Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, October 25, 2014
Technology Networks
 
Register | Sign in
Home Page > Posters
  Posters

First total synthesis of Combretastatin D-2 congeners named Isocorniculatolide A and 11-o-methylisocornicultolide
As a part of our ongoing research in synthesizing the Biologically important Natural Products, here we are reporting First total synthesis of newly isolated isocorniculatolide A and 11-O-methyl corniculatolide A.

Date Posted: 07/06/2012
ePosters.net Ref: EP


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.
Peptide Mimics as a Drug Target for Ebola
University of Utah researchers create a tool to develop treatments for Ebola using Protein Technologies’s peptide synthesizer.
Personalized Ovarian Cancer Vaccines
UConn Researchers have found a new way to identify protein mutations in cancer cells.
Potential Therapy for Myasthenia Gravis
Penn study demonstrates efficacy of potential therapy for autoimmune disorder of muscle weakness.
Candidate H7N9 Avian Flu Vaccine Works Better With Adjuvant
Results of large NIH-sponsored trial demonstrate improved vaccine response when an adjuvant was used.
Monkey Antibodies Help Fight Virus
Details of monkey antibodies against chikungunya virus could help to fight the disease in humans.
Calixar and VirPath Develop an Innovative Manufacturing Process
A new antigens formulation against pandemic flu (A H1N1 virus) proved six times more effective than other vaccines.
New Approach To Arthritis Treatment
A new approach to arthritis treatment, which avoids unforeseen side-effects by delivering drugs exclusively to affected inflamed joints, has been developed by researchers at Queen Mary University of London.
A New Molecule Allows for an Increase in Stem Cell Transplants
A clinical study using UM171 and a new type of bioreactor developed for stem culture will be initiated in December 2014.
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv